Alternative polyadenylation of cyclooxygenase-2

Tyra Hall-Pogan1,2, Haibo Zhang1,3, Bin Tian1,2,3 and Carol S. Lutz1,2,*

1Department of Biochemistry and Molecular Biology, 2Graduate School of Biomedical Sciences and 3Bioinformatics Center, UMDNJ–New Jersey Medical School, Newark, NJ 07101, USA

Received December 10, 2004; Revised April 4, 2005; Accepted April 13, 2005

ABSTRACT

A biologically important human gene, cyclooxygenase-2 (COX-2), has been proposed to be regulated at many levels. While COX-1 is constitutively expressed in cells, COX-2 is inducible and is upregulated in response to many signals. Since increased transcriptional activity accounts for only part of the upregulation of COX-2, we chose to explore other RNA processing mechanisms in the regulation of this gene. We performed a comprehensive bioinformatics survey, the first of its kind known for human COX-2, which revealed that the human COX-2 gene has alternative polyadenylation (proximal and distal sites) and suggested that use of the alternative polyadenylation signals has tissue specificity. We experimentally established this in HepG2 and HT29 cells. We used an in vivo polyadenylation assay to examine the relative strength of the COX-2 proximal and distal polyadenylation signals and have shown that the proximal polyadenylation signal is much weaker than the distal one. The efficiency of utilization of many suboptimal mammalian polyadenylation signals is affected by sequence elements located upstream of the AAUAAA, known as upstream efficiency elements (USES). Here, we used in vivo polyadenylation assays in multiple cell lines to demonstrate that the COX-2 proximal polyadenylation signal contains USEs, mutation of the USEs substantially decreased usage of the proximal signal, and that USE spacing relative to the polyadenylation signal was significant. In addition, mutation of the COX-2 proximal polyadenylation signal to a more optimal sequence enhanced polyadenylation efficiency 3.5-fold. Our data suggest for the first time that alternative polyadenylation of COX-2 is an important post-transcriptional regulatory event.

INTRODUCTION

Cyclooxygenases (COX) are the key and rate-limiting enzymes in the production of prostaglandins [reviewed in (1) and references therein]. The first steps in prostanoid synthesis are the release of arachidonic acid from membrane phospholipids by phospholipases and conversion to prostaglandin H_2 by COX. Prostaglandins play a role in many biological processes, including but not limited to inflammation, bone formation, wound healing and pain perception. Inflammatory cells as well as other types of cells, including fibroblasts and epithelial cells produce prostaglandins (2,3).

Two separate COX genes have been identified, COX-1 and COX-2 (4–10). A spliced variant of COX-1 (COX-3) has also been identified (11). The proteins that these genes encode are ~60% identical at the amino acid level. In contrast, the 3′-untranslated regions (3′-UTRs) of COX-1 and COX-2 are highly divergent. The most striking difference between these genes is in their regulation of expression; COX-1 is constitutively expressed while COX-2 is strongly induced in response to activation by hormones, pro-inflammatory cytokines, growth factors, oncogenes, carcinogens and tumor promoters (1–3,12–15).

The physiological or pathological outcomes of COX-2 activity depend upon its level of expression. COX-2 overexpression is associated with a number of conditions, including cancer, rheumatoid arthritis, seizures and inflammatory disorders [reviewed in (1,16–22)]. In addition, COX-2 upregulation contributes to pain; indeed, inhibition of COX-2 enzymatic activities is responsible for the anti-inflammatory properties of aspirin, indomethacin, ibuprofen and related NSAIDs, such as Vioxx (Rofecoxib) and Celebrex (Celecoxib). Molecular events leading to overexpression of COX-2 have not been definitively characterized. Some studies have clearly demonstrated increased levels of COX-2 mRNA in colorectal adenomas, colon cancer cell lines, adenocarcinomas, gastric cancer, breast cancer, certain ovarian and prostate cancers, and non-small lung cancer (22–33). Enhanced COX-2 mRNA transcription may play a role but enhanced COX-2 protein expression most probably requires post-transcriptional gene
regulation events, such as are mediated through mRNA processing and mRNA turnover. Indeed, the kinetics of transcriptional activation alone cannot account for the sustained induction of COX-2 mRNA by interleukin 1 in vascular endothelial cells (14).

The 3′ end of nearly every fully processed eukaryotic mRNA has a poly(A) tail, which has been suggested to influence mRNA stability, translation and transport (reviewed in (34–37)). Polyadenylation is a two-step process [reviewed in (38–41) and references therein], first involving specific endonucleolytic cleavage (42) at a site determined by binding of polyadenylation factors. The second step involves polymerization of the adenosine (A) tail to an average length of ~200 residues. Most mammalian polyadenylation signals contain the consensus sequence AAUAAA or a close variant between 10 and 35 nt upstream of the actual cleavage and polyadenylation site. AAUAAA is associated with a frequency of ~53% of all human polyadenylation signals and ~59% of all mouse polyadenylation signals (43). This hexamer sequence serves as a binding site for the basal polyadenylation factor cleavage and polyadenylation specificity factor (CPSF) (38–41). Sequences ~14–35 nt downstream of the polyadenylation signal are also known to be involved in directing polyadenylation by serving as a binding site for the basal polyadenylation factor cleavage stimulation factor (CstF) [(38–41,44–52) and references therein]. Elements upstream of the AAUAAA sequences, known as upstream efficiency elements (USEs), have also been characterized that can enhance polyadenylation efficiency, and have been identified in viral and cellular systems (53–66) and references therein]. Spacing between the AAUAAA and the USE significantly influences USE efficiency in enhancing polyadenylation (65). Although USEs are polyadenylation efficiency elements, they may also provide additional functions in proper processing.

As has been appreciated in recent years, 3′ end formation is interconnected to mRNA processing events, as well as to mRNA transcription and transcription termination (40,67–69). This interconnection and execution of a functional mRNA likely results from recognition and utilization of cis- and trans-acting signals.

The 3′-UTR of an mRNA can have a major influence on developmental and tissue-specific regulation of gene expression. In fact, the 3′-UTR has recently been called ‘a molecular hotspot for pathology’ (70). Regulation of gene expression through the 3′-UTR can include alternative polyadenylation, translational control and differential mRNA stability. Preliminary evidence suggests that regulated polyadenylation and mRNA stability may play a pivotal role in COX-2 expression.

The COX-2 gene is made up of 10 exons; the 3′-UTR is contained within exon 10 (71). The COX-2 3′-UTR is larger than average, encompassing ~2.5 kb, and has many interesting features. It has several polyadenylation signals, only two of which are commonly used, resulting in mRNAs of ~2.8 kb using the proximal (with regard to the stop codon) polyadenylation signal or ~4.6 kb using the distal polyadenylation signal (Figure 1). The proximal polyadenylation signal has a non-consensus CPSF binding site (AAUAAA) yet it is used. It is likely that regulation occurs here, resulting in two mRNAs with different RNA metabolism. Curiously, the mRNA that uses the proximal polyadenylation signal contains putative USEs which are similar in sequence and location to those described previously (64–66). The 3′-UTR also has 22 repeats of an AU-rich motif resembling those known to be involved in regulation of mRNA stability (72,73). Recent studies have found that HuR, or a close variant, binds to these AU-rich elements (AREs) (74–76). Other studies have shown additional RNA binding proteins also may bind to the COX-2 3′-UTR (77–79). Additionally, it has been

---

**Figure 1.** Schematic representation of the human COX-2 3′-UTR. Diagram of the 3′-UTR of the human COX-2 gene highlighting the major polyadenylation signals; resulting mRNAs are also depicted. Putative auxiliary USEs are represented by hatched boxes; checkered boxes represent CstF-binding sites; AREs are represented by dotted ovals. Bottom: sequence of a portion of the COX-2 proximal polyadenylation signal. Putative USEs are italicized, underlined and noted above the sequence.
suggested, but not proven, that tissue specificity might play a role in COX-2 polyadenylation site choice (80,81). The significance of the different tissue distributions of these isoforms has not yet been addressed, and most probably will provide significant revelations with regard to COX-2 expression control.

Alternative polyadenylation of the COX-2 3′-UTR results in two mRNAs differing only in their 3′ ends. Therefore, the choice of a particular polyadenylation site likely involves specific cis- and trans-acting factors, resulting in RNAs with different metabolism, and ultimately will influence the cytoplasmic fate of the mRNA. This study examines the regulation of alternative 3′ end formation in the human COX-2 pre-mRNA. We demonstrate that alternative polyadenylation does occur in the COX-2 mRNA and that the two major, utilized polyadenylation signals (proximal and distal) are different in strength and composition. We also show that alternative polyadenylation of the COX-2 mRNA occurs in a tissue-specific fashion in cells that endogenously overexpress COX-2. The proximal polyadenylation signal contains auxiliary USEs that are important for its efficient usage. These experiments suggest that alternative polyadenylation of COX-2 mRNA is an important level of gene expression regulation, because polyadenylation signal choice will include or exclude additional regulatory elements that may influence the metabolic fate of the mRNA.

MATERIALS AND METHODS

Plasmids

Primers for PCR to amplify the proximal and distal polyadenylation signals of the human COX-2 3′-UTR were prepared by the Molecular Resource Facility of UMDNJ-NJMS, and had the sequences as listed in Supplementary Table 2. The COX-2 proximal and distal primers contained BamHI (forward) and PstI (reverse) restriction sites to allow insertion into appropriately digested vectors. Human genomic DNA was used as a template to amplify by PCR the appropriate COX-2 proximal and distal polyadenylation signals and flanking sequences for insertion into pGem4 and pCB vector. The pCB vector (a gift from David Fritz, UMDNJ) (64) has a multiple cloning site downstream of the CMV promoter and upstream of the bovine growth hormone (BGH) polyadenylation signal. This vector also includes intron 1 of the rabbit β-globin gene accompanied by the splice donor and acceptor sites. Thus, pCB-proximal and pCB-distal were created.

The USE mutants, the hexamer mutant and the non-specific mutant were made by PCR-based site-directed mutagenesis using the Stratagene QuikChange kit as per the manufacturer’s protocols using the pCB-proximal vector as the template. The USE and non-specific mutant were designed to create BglII restriction sites for ease in screening. The COX-2 proximal 5′ deletion (S) mutant was made by PCR using primers described in Supplementary Table 2. This construct is lacking 115 bases upstream of the COX-2 proximal polyadenylation signal.

The USE mutant 1 has the sequence AAAGATCTAA instead of the wild-type sequence AATTTGAA; the USE mutant 2 has the sequence AAAGCTTA instead of the wild-type sequence AATTCCTAA; the USE mutant 3 has the sequence GAGATCTTA instead of the wild-type GATTCCTTA. The USE mutants 1, 3 and 2, 3 had both USEs mutated as described above.

The pCB-proximal–distal-BGH construct was made in the following manner. The COX-2 distal polyadenylation signal was removed from pCB-distal by BamHI and PstI, then the ends were blunted and inserted into pCB-proximal which had been digested with EcoRV. Therefore, pCB-proximal–distal-BGH has three polyadenylation signals in tandem. The pCB-proximal–distal construct was made by digesting pCB-proximal–distal-BGH with XhoI and KpnI to remove the BGH polyadenylation signal. Therefore, pCB-proximal–distal has both COX-2 polyadenylation signals in tandem.

All constructs were transformed into Escherichia coli XL1-Blue cells. Positive clones were sequenced and assayed for expression of the appropriately sized insert. Constructs were verified by sequencing (Molecular Resource Facility, UMDNJ-NJMS). SVL RNA was used as described previously (66).

Rapid site-directed mutagenesis using two PCR-generated DNA fragments

The USE double (USE mut 1, 2) and triple (USE mut 1, 2, 3) mutations were generated by standard PCR using KOD polymerase and using the upstream (5′) wild-type COX-2 proximal primer containing a BamHI restriction site and a downstream primer (3′, USE 1, 2 R) containing the respective site-directed mutagenic base pair changes. Then the upstream mutagenic primer (5′, USE 1, 2 F) was used in standard PCR using KOD polymerase and the wild-type COX-2 proximal downstream primer (3′, containing a PstI restriction site. The USE 1, 2 mut was prepared using COX-2 proximal wild-type DNA template in the PCR, while the USE 1, 2, 3 mut was prepared using USE 3 mut DNA template. The products of the above two sets of PCR steps were re-amplified using the 5′ and 3′ wild-type COX-2 proximal primers and the resulting 268 bp fragment was cloned into the BamHI/PstI sites of the pCB vector.

Mammalian cell culture

HeLa, MDA-MD231 and HepG2 cells were maintained in DMEM (Life Technologies) supplemented with 10% fetal bovine serum (Sigma) and 1% penicillin–streptomycin (Life Technologies). HT29 cells were maintained in RPMI-1640 Medium (Life Technologies) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin.

Transfection

HeLa or MDA-MB-231 cells (7 x 10⁵ cells/well) were seeded in 60 mm plates ~12 h before transfection. When cells reached 80% confluency, they were transfected using LT-1 reagent (Mirus). Plasmid DNA (2.8 μg) was diluted in 180 μl of serum-free medium to which 6 μl of LT-1 was added and the mixture was incubated at room temperature for 20 min. Following the addition of 1 ml complete medium to the transfection mixture, the medium on the cells was removed and replaced with the entire transfection cocktail. After 24 h, cells were washed once with 1× phosphate-buffered saline (PBS). Cells were scraped and collected into 1 ml PBS and transferred into microcentrifuge tubes. Cells were then centrifuged at 7000 r.p.m. for 5 min (4500 g in an Eppendorf microcentrifuge). The PBS was aspirated and total RNA was extracted immediately from the cell pellet as described below.
Total RNA isolation and RNase protection assay

To determine polyadenylation signal use in vivo, total RNA from transfected cells was assayed by RNase protection. Total RNA was extracted from the cell pellet using either the TRIZOL method (Invitrogen) or the RNeasy Mini Kit (Qiagen) according to the manufacturer’s spin protocol for isolation of total RNA from animal cells. For RNase protection assay reactions, 5 μg of total RNA was used per reaction. Probe RNA for the in vivo polyadenylation assay was prepared as described below. The reporter and/or endogenous RNA levels were determined by RNase protection using the RPAIII kit (Ambion Inc., Austin, TX). The RNA was then analyzed on 5% polyacrylamide–8 M urea gels as described previously (64). The ratio of the reporter assay and endogenous band was used to determine polyadenylation efficiency.

Bioinformatics

Expressed sequence tag (EST) sequences corresponding to the human COX-2 gene and their tissue information were obtained from dbEST (March 2004 version; National Center for Biotechnology Information, NCBI), according to the UniGene database (March 2004 version; NCBI). Sequences were aligned to the human genome and polyadenylation sites were determined by using a method described previously ([43] and references therein). ESTs with poly(A) tail sequence were used to infer polyadenylation sites.

Statistical analyses

Results are expressed as ±SD of the mean, and analyses were performed by two-sample one-tailed Student’s t-test. *P*-values <0.05 were considered significant.

RESULTS

EST surveys suggest existence of multiple polyadenylation signals for the human COX-2 gene with tissue specificity

Because alternative polyadenylation is potentially a key regulator of human COX-2 expression, we systematically investigated the mechanism controlling alternative 3′ end formation. Using a bioinformatics approach, we have surveyed the current EST database for human COX-2 mRNAs that would represent utilization of either the proximal or the distal COX-2 polyadenylation signal. Using ESTs with poly(A) tail sequence (see Materials and Methods; B. Tian and C. S. Lutz, unpublished data), we identified three COX-2 polyadenylation signals, named proximal 1, proximal 2 and distal, respectively (Table 1, top). The closed diamonds represent ESTs containing poly(A) tail sequence. The open circles denote ESTs that do not have poly(A) tail sequence. Since these open circles are located after proximal 2, they indirectly support the use of the distal polyadenylation signal, assuming there is no other poly(A) signal between proximal 2 and distal. The distance between proximal 1 and proximal 2 is ~400 nt, and between proximal 2 and distal is a little less than 2000 nt. Since proximal 1 lacks a definable CstF binding site and previous northern blot data only support transcript sizes resulting from proximal 2 and distal signal usage (80,81), we focused on proximal 2, which we will refer to simply as ‘proximal’ throughout the rest of our study. The distance between proximal and distal from this EST survey is in good agreement with published data, and the distance between proximal 1 and proximal 2 is ~2000 nt.

Immunoblot analysis

Cell lysates were prepared by incubating 1.5 × 10⁶ cells on ice for 30 min in a solution containing 1% NP-40, 150 mM NaCl and 50 mM Tris–HCl (pH 8.0), plus phenylmethylsulfonyl fluoride (50 μg/ml), leupeptin, aprotinin and pepstatin A (each at 1 μg/ml). Protein from cleared lysate (75 μg) was separated by 10% SDS–PAGE, then blotted onto nitrocellulose membrane and blocked in 5% non-fat dry milk. Primary antibody incubations were performed at a dilution of 1:100 in blocking solution for 3 h at room temperature. Mouse anti-human COX-2 monoclonal antibody and recombinant human COX-2 protein were purchased from Cayman Chemical (Ann Arbor, MI). Goat-antimouse horseradish peroxidase-conjugated secondary antibody (ICN) was used at a dilution of 1:5000 for 1 h at room temperature. Visualization of bound antibodies was accomplished through chemiluminescence using an ECL kit (Amersham Pharmacia Biosciences) and autoradiography.
with those reported in previous studies ([80,81] and Figure 1). Also in Table 1 are cDNA library IDs for the ESTs found (first column in Table 1) and tissue and organ information if known on the biological source of the cDNA libraries (last two columns in Table 1). Use of the COX-2 proximal and distal polyadenylation signals are noted by the numbers of ESTs that appeared from each library.

Moreover, our data are comprehensive; all available ESTs corresponding to human COX-2 were used.

Table 1. Expressed sequence tag survey result of COX-2 polyadenylation signals

| LIB_ID | P1 | P2 | D  | Di | Organ                      | Tissue                        |
|--------|----|----|----|----|----------------------------|-------------------------------|
| 9821   | 1  | 1  | 1  |    | Pancreas                    | Islets of Langerhans          |
| 12072  | 1  | 1  |    |    | Lung                        | Alveolar macrophage           |
| 423    |    |    |    | 1  | Senescent fibroblast        |                               |
| 9692   | 1  |    |    |    | Human skeletal muscle       |                               |
| 1410   | 3  | 2  | 3  |    | Prostate                    |                               |
| 1184   | 1  |    |    |    | Pooled                      |                               |
| 12540  | 1  |    |    |    | Liver                       |                               |
| 12798  | 1  |    |    |    |                            |                               |
| 9691   | 2  |    |    |    |                            |                               |
| 464    |    |    | 1  |    | Lung                        | Lung carcinoma                |
| 537    | 1  |    |    |    | Colonic                     | Tumor                         |
| 938    | 1  | 1  |    |    | Kidney                      |                               |
| 1045   | 1  |    |    |    | Stomach                     | Poorly differentiated adenocarcinoma with signet ring cell features |
| 1449   | 1  | 1  |    |    | Uterus                      | Well-differentiated endometrial adenocarcinoma, seven pooled tumors |
| 1461   | 1  |    |    |    | Lung                        | Squamous cell carcinoma, poorly differentiated (four pooled tumors, including primary and metastatic) |
| 1661   | 1  |    |    |    | Lung                        | Two pooled squamous cell carcinomas |
| 2298   | 1  |    |    |    | Lung                        | Myeloid cells, 18 pooled CML cases, BCR/ABL rearrangement positive, includes both chronic phase and myeloid blast crisis |
| 2460   | 1  |    |    |    | Whole blood                 | Trabecular meshwork           |
| 5488   | 1  |    |    |    |                            |                               |
| 8613   | 1  |    |    |    | Blood                       | Lymphocyte                    |
| 10398  | 1  |    |    |    | Lung                        | Primary lung epithelial cells |
| 10411  | 1  |    |    |    | Lung                        | Metastatic chondrosarcoma     |
| 10413  | 1  | 1  |    |    | Left pelvis                 | Chondrosarcoma                |
| 10416  | 1  |    |    |    | Left pelvis                 | Chondrosarcoma                |
| 10424  | 1  |    |    |    | Placenta                    | Placenta                      |
| 13024  | 1  |    |    |    |                            |                               |
| 13833  | 1  |    |    |    |                            |                               |
| 271    | 2  | 1  |    |    | Placenta                    | Normal prostate               |
| 910    | 2  | 1  |    |    | Prostate                    | Two pooled high-grade transitional cell tumors |
| 2457   | 2  | 1  |    |    | Genitourinary tract         |                               |
| 313    | 3  |    |    |    |                            |                               |
| 655    | 1  |    |    |    | Bone                        |                               |
| 787    | 1  |    |    |    | Prostate                    |                               |
| 1076   | 1  |    |    |    | Lung                        | Carcinoid                     |
| 2393   | 1  |    |    |    |                            |                               |
| 4723   | 1  |    |    |    |                            |                               |
| 4761   | 2  |    |    |    | Breast_normal               |                               |
| 5191   | 1  |    |    |    | Head_and neck               |                               |
| 5566   | 1  |    |    |    | Bone marrow                 | From chronic myelogenous leukemia |
| 5949   | 1  |    |    |    | Brain                       | Glioblastoma                  |
| 6975   | 1  |    |    |    | Bone marrow                 |                               |
| 8684   | 1  |    |    |    | Skin                        |                               |
| 10426  | 1  |    |    |    | Mixed                       |                               |
| 10925  | 1  |    |    |    | Left pelvis                 | Chondrosarcoma grade II       |
| 11912  | 1  |    |    |    | Lung                        | Human lung epithelial cells   |
| 13018  | 1  |    |    |    |                            |                               |

Top: genomic sequence of COX-2 3'-UTR containing three polyadenylation signals is depicted schematically. The position of proximal 1 is arbitrarily set as 0. Closed diamonds denote the locations of poly(A) signals supported by ESTs with poly(A) tail sequence. Open circles are the locations of the 3' end of ESTs without poly(A) tail sequence. Bottom: LIB_ID corresponds to cDNA library ID in the dbEST database. P1, proximal 1; P2, proximal 2; D, distal; and D1, distal supported by ESTs without poly(A) tail sequence (explained in the text).
We would like to highlight that (i) both COX-2 polyadenylation signals are used in vivo; (ii) there are different tissue patterns/distributions and (iii) this is a much larger-scale analysis than has previously been reported. Importantly, these tissue-specific distribution patterns and the polyadenylation signals utilized closely match smaller scale, reported tissue specificity (80,81), with use of the proximal form notably predominating liver, while the distal form notably predominates in colon. Our data underscore the biological relevance of our study and highlight the need for understanding the mechanisms of regulation that are involved.

Endogenous COX-2 mRNAs are polyadenylated at different sites in cell lines representing different tissues

To further evaluate the biological usage of both polyadenylation signals with regard to the tissue specificity noted by our bioinformatics analysis, we chose two established human cancer cell lines, HT29 (colon) and HepG2 (liver). Like many colon cancer-derived cell lines (75), HT29 cells constitutively express COX-2 since endogenous COX-2 protein can be readily detected by western blotting in HT29 extracts (Figure 2A, lane 2). The constitutive expression of COX-2 in hepatocellular carcinoma cells such as HepG2 has been debated in the literature. In our hands, COX-2 protein was detected in HepG2 extract indicating that COX-2 is expressing in this hepatocellular carcinoma cell line (Figure 2A, lane 3). The levels of endogenous COX-2 protein appear to be lower in HepG2 cells than in HT29 cells. As a loading control, we probed the same western blot with an antibody specific for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and found GAPDH to be equivalent in each lane (data not shown).

It has been reported that the distal COX-2 polyadenylation signal is used in primary colon samples and that the proximal polyadenylation signal is used in liver samples as assayed by northern blots, but this conclusion was based purely on transcript size (81). We therefore decided to perform our assay based on a more precise method of analyzing polyadenylation signal usage. This assay allows us to specifically identify use of the proximal and distal polyadenylation signals (Figure 2B; see also Figure 1). Total RNA was extracted from HT29 and HepG2 cells and this RNA was used in standard RNase

![Figure 2. Tissue-specific alternative polyadenylation of COX-2 in HT29 and HepG2 cells. (A) Western blot of 75 μg total protein cell extract from HT29 and HepG2 cells using an anti-COX-2 monoclonal antibody. Lane 1, 1 μg recombinant COX-2 protein. (B and C) RNase protection assays using endogenous RNA from HT29 (B) and HepG2 (C) cells along with COX-2 proximal and/or distal probes. The data shown in (B), lane 2, illustrate that HT29 cells primarily use the COX-2 distal polyadenylation signal. (C) HepG2 cells utilizing the COX-2 proximal signal in lane 1 and the distal signal in lane 2. The band corresponding to utilization of the COX-2 proximal polyadenylation signal is marked with an asterisk; the band corresponding to utilization of the COX-2 distal polyadenylation signal is marked with an arrow.](image-url)
After confirming that both COX-2 polyadenylation signals are used in vivo, we next applied our in vivo polyadenylation assays (64) to address directly the mechanism controlling use of the COX-2 proximal and distal polyadenylation signals. We first addressed how the suboptimal AUUAAA proximal COX-2 polyadenylation signal behaved in our system. The apparent weakness of this polyadenylation signal was postulated based upon its divergence from the consensus AAUAAA CPSF binding site. We cloned a 268 bp fragment by PCR including the human COX-2 proximal polyadenylation signal and flanking sequences into our two polyadenylation signal reporter vector pCβS, diagrammed in Figure 3A. In this series of experiments, the proximal signal was inserted into the signal 1 site while the BGH signal occupied the signal 2 site. This pCβS-COX-2-proximal construct was then transfected into HeLa or MDA-MB-231 (breast cancer) cells. Total RNA was isolated after 24 h, RNase protection assays were performed using the antisense probe to the pCβS-COX-2-proximal construct (Figure 3A), and the results were quantified using a PhosphorImager and ImageQuant software. RNase protection assays will produce a protected fragment of 168 bases if the COX-2 proximal polyadenylation signal is used; utilization of the BGH signal will produce a protected fragment of 410 bases. We found that polyadenylation at the COX-2 proximal signal compared with that at the BGH signal occurred in a ratio of 1:3, indicating that the proximal COX-2 signal is indeed suboptimal (Figure 3B, lane 4 and Figure 3C).

We next compared polyadenylation using the COX-2 distal polyadenylation signal to BGH by the same type of assay. We cloned a 454 bp fragment by PCR containing the COX-2 distal polyadenylation signal into the pCβS vector, with the COX-2 distal signal occupying the polyadenylation signal 1 site in the reporter vector. Use of the COX-2 distal polyadenylation signal in the RNase protection assay will protect a fragment of 235 bases. Because the distal polyadenylation signal has a consensus AAUAAA, we predicted that this signal would be stronger than the proximal polyadenylation signal of COX-2. Indeed, the COX-2 distal polyadenylation signal was stronger than the COX-2 proximal signal, and was used ~45% of the time compared with polyadenylation at the BGH signal of ~55% (Figure 3B, lane 5 and Figure 3D). In this set of experiments, the band corresponding to BGH migrated slightly faster than expected. This result was reproducible in this assay, and has been observed previously using the same assay and vector (64). These assays were performed in HeLa or MDA-MB-231 cells where there is no detectable endogenous COX-2 protein or mRNA (data not shown). These data demonstrate that although both COX-2 polyadenylation signals are used, the COX-2 proximal signal is indeed weak and the COX-2 distal signal is stronger as compared with the internal control.

Since the COX-2 polyadenylation signals are normally in tandem in the COX-2 3’-UTR, and therefore may be in competition with each other, we measured their relative use in a similar assay as described above. Here, the COX-2 proximal and distal polyadenylation signals were both placed in their respective order in the pCβS reporter plasmid while keeping the BGH polyadenylation signal intact (pCβS-proximal-distal-BGH). After transfection into HeLa cells, RNase protection assays were performed as described above. In this context, the relative use of COX-2 proximal signal was 14.3%, the relative use of the COX-2 distal signal was 53.5%, and the relative use of the BGH polyadenylation signal was 32.2%, giving a ratio of proximal/distal/BGH of 1:3.8:2.3 (data not shown). When the BGH polyadenylation signal was removed to produce a tandem construct (pCβS-proximal-distal), transfected into HeLa or MDA-MB-231 cells, RNA isolated and RNase protection assays performed, the ratio of proximal/distal polyadenylation signal usage was 1:3, not appreciably different from when the BGH was present (Figure 3B, lane 7 and Figure 3E). Note that the creation of the pCβS-proximal-distal construct caused the resulting protected fragments to differ in size slightly from the results obtained using either the pCβS-proximal or the pCβS-distal alone. These data demonstrate that the COX-2 proximal polyadenylation signal does not compete significantly with the distal polyadenylation signal in tandem.

Effect of mutation of core and auxiliary polyadenylation elements in the suboptimal COX-2 proximal polyadenylation signal

Since the COX-2 proximal core polyadenylation signal is AUUAAA, and therefore differs from the consensus AAUAAA, we showed that it was suboptimal in vivo (Figure 3B, lanes 4 and 7). Previous in vitro studies in the Wickens and Shenk laboratories had mutated the consensus AAUAAA to every base at each position (82,83). These studies had shown in vitro that while AUUAAA worked better than any other derivative of AAUAAA, it still did not perform as well as the consensus AAUAAA. To further prove this in vivo, we mutated the AAUAAA to the consensus sequence AAUAAC using site-directed mutagenesis (see Figure 4A for diagram). We then measured polyadenylation signal use (relative to BGH polyadenylation signal use) by RNase protection assays as described above. Here, we have calculated fold-induction at the proximal polyadenylation signal; so utilization at the wild-type proximal signal was set at a value of 1. We found that this single change, AUUAAA to AAUAAA mutation, enhanced polyadenylation by 3.5-fold over the level of polyadenylation at the COX-2 proximal polyadenylation signal (Figure 4B), thus acting as a positive mutant. Similar results were found using MDA-MB-231 cells (data not shown). These results confirmed directly for the first time in vivo...
that the difference between an ‘optimal’ AAUAAA and a ‘suboptimal’ AUUAAA core polyadenylation signal is operationally real.

Polyadenylation efficiency can be enhanced by the presence of auxiliary elements located upstream of the CPSF binding site, known as USEs (64–66). Sequences upstream of the COX-2 proximal polyadenylation signal that we identified bear striking similarity to the consensus UAU2-5GUNA USE sequence previously studied in our laboratory. The COX-2 USEs are located 58, 49 and 6 bases upstream of the proximal polyadenylation signal (Figure 4A). We predicted that these putative USEs would affect polyadenylation efficiency of the

---

**Figure 4**

**A**

A diagram showing the positions of PA Signals #1 and #2 with the CMV promoter and T7 promoter. The sequence is labeled as Full Length Probe.

**B**

A gel showing undigested probe with marker and digested probes labeled as Proximal vs Distal and Proximal vs BGH. Proximal samples are labeled with a black arrow, and Distal samples are labeled with a gray arrow.

**C**

Graph showing % Utilization of PA Signal for pCβS-proximal. HeLa and MDA-MB231 cell lines are compared.

**D**

Graph showing % Utilization of PA Signal for pCβS-distal. HeLa and MDA-MB231 cell lines are compared.

**E**

Graph showing % Utilization of PA Signal for pCβS-proximal-distal. HeLa and MDA-MB231 cell lines are compared.
suboptimal COX-2 proximal polyadenylation signal. In order to experimentally address this prediction, we mutated the USEs in the context of our in vivo polyadenylation construct. Mutants were prepared by PCR-based site-directed mutagenesis in each of the three putative USEs, as well as a non-specific mutant in a non-USE region upstream of the COX-2 proximal polyadenylation signal (Figure 4A). These constructs were then transfected into HeLa (or MDA-MB-231 cells; data not shown), total RNA was isolated and RNase protection assays were performed as described above. The results are shown in Figure 4C. Mutation of each USE was increasingly more deleterious as the USE mutation approached the suboptimal core polyadenylation hexamer element AUUAAA, with USE 3 mutation alone decreasing in vivo polyadenylation to approximately half of the wild-type level (Figure 4C). Mutation of the USEs in duplicate (USE 1,2 mut; USE 2,3 mut; USE 1,3 mut) resulted in approximately the same level of reduced polyadenylation efficiency as the USE 3 mut alone (Figure 4C). However, the triple USE mutation (USE 1,2,3 mut) resulted in a significant decrease in polyadenylation signal utilization (Figure 4C). Deletion of the entire USE-containing region in the 5′Δ mutant almost abolished polyadenylation at the COX-2 proximal polyadenylation signal (Figure 4C). Taken together, these data suggest that the USEs may have additive or synergistic effects. These data also suggest that the USEs are important polyadenylation efficiency elements in the COX-2 proximal polyadenylation signal, and perhaps ensure that the proximal signal is utilized.

**USE competition for polyadenylation suggests that a trans-acting factor could be influencing polyadenylation at signals containing USEs**

To further define a functional role of the USEs as auxiliary efficiency elements, we performed in vitro polyadenylation assays using specific competitors. Previously, we have shown that in vitro polyadenylation reactions containing an SV40 late polyadenylation signal substrate RNA (SVL) could be inhibited specifically by oligoribonucleotides representing the SV40 USE motifs (66), and that polyadenylation in vitro of human COL1A2 substrate RNA can be inhibited by a COL1A2 USE oligoribonucleotide (64). We now prepared an oligoribonucleotide that represents COX-2 USE 3, and added this oligoribonucleotide to in vitro polyadenylation reactions containing HeLa nuclear extract and a 32P-labeled SVL prepared by in vitro transcription using SP6 polymerase. This substrate RNA was chosen because it works well for in vitro polyadenylation, and because the USEs in SV40 are similar to those found in the proximal COX-2 polyadenylation signal. The data are shown in Figure 5A and B. Figure 5A demonstrates graphically that the COX-2 USE oligoribonucleotide specifically inhibited SVL polyadenylation in vitro, whereas a non-specific oligoribonucleotide had no significant effect on SVL polyadenylation. An additional non-specific oligonucleotide also had no effect (data not shown) (64). Figure 5B shows representative experiments. Lane 1 in Figure 5B, both upper and lower panels, represents a reaction performed in the absence of competitor oligoribonucleotides and demonstrates that the SVL RNA was efficiently polyadenylated in the in vitro system. Interestingly, 50 pmol of the COX-2 USE 3 oligoribonucleotide specifically inhibited polyadenylation to <10% of the control reaction (Figure 5B, upper panel). This amount is similar to other USE oligoribonucleotide inhibition reactions (64,66). The non-specific oligo did not inhibit in vitro polyadenylation (Figure 5B, lower panel). In vitro polyadenylation of a non-USE containing polyadenylation signal, AAV, was also not inhibited by the addition of the COX-2 USE 3 at similar concentrations as expected (Figure 5C). Polyadenylation of AAV was also not affected by addition of the non-specific oligonucleotides as expected (Figure 5C). Taken together, these data demonstrate that the COX-2 USE 3 oligoribonucleotide specifically binds and sequesters a putative common factor(s) important for polyadenylation, and suggest that the similarity to the SV40 USE motifs is functionally significant.

**DISCUSSION**

Polyadenylation is a useful and underexplored mechanism of regulating gene expression, and this regulation is partially implied by the complex nature of this process. Alternative polyadenylation can generate mature transcripts that only differ in their 3′ ends. Efficiency of processing is another level at which regulation can occur, since most pre-mRNAs in the cell are not efficiently processed, and therefore, even small changes in the overall processing efficiency of a particular pre-mRNA may have a great effect on ultimate protein levels. Experimental evidence has demonstrated that poly(A) signal strength directly influences the amount of mature, exported mRNA (84,85).
Our objective in this study was to accurately define and characterize alternative polyadenylation as it applied to the human COX-2 3′-UTR. Interestingly, the size and scheme of the 3′-UTR is conserved among human, chimpanzee, mouse and rat COX-2 genes, along with the two polyadenylation signals, suggesting that the importance of alternative polyadenylation plays a key regulatory function (B. Tian, H. Zhang, and C. S. Lutz, unpublished data). Indeed, the
sequences for USEs 1 and 2 are exact matches in the 3'UTR of mouse COX-2 homolog (B. Tian, H. Zhang, and C. S. Lutz, unpublished data). Choice of a particular polyadenylation signal may result in mRNAs with different stability or different translation efficiency, which has direct consequences for how much protein product is ultimately produced. Therefore, polyadenylation signal choice can be a key step in mRNA maturation. Our work examined the relative strength and composition of the COX-2 proximal and distal polyadenylation signals. We have shown that the COX-2 proximal and COX-2 distal polyadenylation signals are utilized in an in vivo polyadenylation assay. We further demonstrated that the use of these COX-2 polyadenylation signals is regulated in a tissuespecific manner. We propose that while basal polyadenylation of these signals does occur experimentally in cell types that do not normally express COX-2 mRNA (HeLa and MDA-MB-231), the cell-type specific utilization of COX-2 proximal and distal polyadenylation signals may require additional as yet unidentified factors.

Additionally, we have demonstrated that a suboptimal CPSF binding site (AUUAAA) is truly weaker than the canonical CPSF binding site, AAUAAA. Taken together, the data suggest a working hypothesis, shown in Figure 6, for polyadenylation signal choice, as well as for possible correlations between polyadenylation signal choice and resulting mRNA stability as postulated (81).

Our model (Figure 6) suggests that use of the COX-2 proximal polyadenylation signal results in a shorter mRNA, while use of the COX-2 distal polyadenylation signal results in a longer mRNA. Use of the proximal polyadenylation signal would exclude a portion of the 3'UTR, which may contain important regulatory elements, for example, elements that regulate mRNA instability. The best characterized 3'UTR sequences that cause mRNA instability are the AREs found in many short-lived mRNAs such as cytokines, growth factors and proto-oncogenes (72,73). The 3'UTR of COX-2 is complex and has many AREs (Figure 1). Currently, data in the literature conflict with regard to which form of COX-2 is more stable. It has been shown that removal of some sequences upstream of the COX-2 proximal polyadenylation signal containing some of the AREs confers increased stability to a heterologous reporter (86), while other data have shown that this same region can transfer instability to a heterologous reporter (87,88). Additionally, the longer COX-2 mRNA has been reported to be the more unstable form as revealed by northern blotting of the COX-2 mRNA while the shorter form is generally thought to be the more stable form (81). While our study has not addressed the questions of stability directly, our study underscores the importance of understanding how alternative polyadenylation of COX-2 is regulated.

We have also demonstrated here that the USEs present in the suboptimal COX-2 proximal polyadenylation signal have a significant effect on in vivo polyadenylation of that signal, since mutation or deletion of the USEs has a substantial effect (Figure 4C). We suggest that the presence of the USEs in the

---

**Figure 4.** A positive mutant and mutation of the USEs influence use of the COX-2 proximal polyadenylation signal. (A) Diagram showing COX-2 proximal polyadenylation signal and mutations prepared. Closed rectangles represent mutations; hatched rectangles represent USEs; and checkered boxes represent the CstF binding site. (B) Mutants were prepared of the COX-2 proximal polyadenylation signal by site-directed mutagenesis and were cloned into pCJS, transfected into HeLa cells, RNA was isolated after 24 h, and RNase protection assays were performed. Quantification of four independent experiments is shown here. Constructs are shown on the x-axis; fold-induction of polyadenylation at the COX-2 proximal signal is shown on the y-axis. Error bars represent SD. All P-values were <0.0029. (C) USE single mutants, double mutants and the triple mutant, as well as the 5'Δ mutant were prepared as described, transfected into HeLa cells, RNA was isolated after 24 h, and RNase protection assays were performed. Quantification of three independent experiments is shown here. Constructs are shown on the x-axis; fold-induction of polyadenylation at the COX-2 proximal signal is shown on the y-axis. Error bars represent SD. All P-values were <0.0017.
COX-2 proximal polyadenylation signal ensure its usage, possibly by supporting and enhancing assembly of the basal polyadenylation machinery on the polyadenylation signal, or by serving as a trans-acting factor binding site which may recruit or enhance interactions with the basal polyadenylation machinery. These explanations are not mutually exclusive. Additionally, tissue-specific factors may be involved since we have shown tissue-specific utilization occurs at the COX-2 proximal polyadenylation signal. These details remain to be explored.

Figure 5. Competition studies suggest USE binding factors influence the processing efficiency of COX-2 proximal polyadenylation signal. (A) Graphical representation of in vitro competitions using SVL and either COX-2 USE oligoribonucleotide (squares) or non-specific oligoribonucleotide (diamonds). Numbers on the x-axis represent pmol of competitor added, numbers on the y-axis represent percent polyadenylation. This quantification represents the average of three independent experiments. Error bars represent SD. (B) Representative in vitro polyadenylation reactions using SV40 late polyadenylation signal RNA as the substrate RNA and increasing amounts of either COX-2 USE oligoribonucleotide as competitor (upper panel) and non-specific oligoribonucleotide as competitor (lower panel). Amounts of competitor used in both sets of reactions are as follows: lane 1, no competitor; lane 2, 1 pmol competitor; lane 3, 10 pmol; lane 4, 20 pmol; lane 5, 37 pmol; lane 6, 50 pmol; and lane 7, 75 pmol. (C) Graphical representation of in vitro competitions using AAV substrate RNA and either COX-2 USE oligoribonucleotide (squares) or non-specific oligoribonucleotide (diamonds).
SUPPLEMENTARY MATERIAL

Supplementary Material is available at NAR Online.

ACKNOWLEDGEMENTS

We thank the members of the Lutz, O’Connor, Rogers, Bellofatto, Modak and Wilusz laboratories for helpful experimental suggestions and comments on this manuscript. Special thanks to David Fritz for helpful suggestions and Matias Elijovich for technical assistance. This work was funded by American Cancer Society Grant RPG-00-265-01-GMC and NSF award MCB-0426195 to C.S.L. Funding to pay the Open Access publication charges for this article was provided by NSF award MCB-0426195.

Conflict of interest statement. None declared.

REFERENCES

1. Hla,T., Bishop-Bailey,D., Liu,C.H., Schaefers,H.J. and Trifan,O.C. (1999) Cyclooxygenase-1 and -2 isoenzymes. Int. J. Biochem. Cell Biol., 31, 551–557.
2. Kelley,D.J., Mestre,J.R., Subbaramaiah,K., Sacks,P.G., Schantz,T., Tanabc,T., Inoue,H., Ramonetti,J.T. and Dannenberg,A.J. (1997) Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis, 18, 795–799.
3. DuBois,R.N., Awad,J., Morrow,J., Roberts,L.J. and Bishop,P.R. (1994) Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor alpha and phorbol ester. J. Clin. Invest., 93, 493–498.
4. Hla,T., Farrell,M., Kumar,A. and Bailey,J.M. (1986) Isolation of the cDNA for human prostaglandin H synthase. Prostaglandins, 32, 829–845.
5. DeWitt,D.L. and Smith,W.L. (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from complementary DNA sequence. Proc. Natl Acad. Sci. USA, 85, 1412–1416.
6. Merlie,J.P., Fagan,D., Mudd,J. and Needleman,P. (1988) Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxidase synthase (cyclooxygenase). J. Biol. Chem., 263, 3550–3553.
7. Hla,T. and Neilson,K. (1992) Human cyclooxygenase-2 cDNA. Proc. Natl Acad. Sci. USA, 89, 7384–7388.
8. O’Banion,M.K., Winn,V.D. and Yong,D.A. (1992) cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl Acad. Sci. USA, 89, 4888–4892.
9. Xie,W., Cipman,J.G., Robertson,D.L., Erikson,R.L. and Simmons,D.L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA, 88, 2692–2696.
10. Garavito,R. and Mulichak,A. (2002) The structure of mammalian cyclooxygenases. Annu. Rev. Biomol. Struct., 32, 183–206.
11. Chandrasekharan,N.V., Dai,H., Roos,K.L.T., Evanson,N.K., Tomsik,J., Elton,T.S. and Simmons,D.L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc. Natl Acad. Sci. USA, 99, 13926–13931.
12. Bazan,N.G., Fletcher,B.S., Herschmann,H.R. and Mukherjee,P.K. (1994) Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc. Natl Acad. Sci. USA, 91, 5252–5256.
13. Hla,T. and MacRae,T. (1991) Cyclooxygenase gene expression is down-regulated by heparin-binding (acidic fibroblast) growth factor-1 in human endothelial cells. J. Biol. Chem., 266, 24059–24063.

14. Ristimäki,A., Garfinkel,S., Wessendorf,J., Maciag,T. and Hla,T. (1994) Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J. Biol. Chem., 269, 11769–11775.

15. O'Banion,M.K., Miller,J.C., Lytton,J.W., Kaplan,M.D. and Coleman,P.D. (1996) Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J. Neurochem., 66, 2532–40.

16. Bazan,N.G. (2001) COX-2 as a multifunctional neuronal modulator. Nature Med., 7, 414–415.

17. Bishop-Bailey,D., Malatau,Y., Warner,T.D., Hla,T. and Mitchell,J.A. (2002) Prostaglandins and the regulation of tumor growth. J. Environ. Pathol. Toxicol. Oncol., 21, 93–101.

18. Hla,T., Ristimäki,A., Appleby,S. and Barriocanal,J.G. (1993) Cyclooxygenase gene expression in inflammation and angiogenesis. Ann. N.Y. Acad. Sci., 696, 197–204.

19. Williams,C.S., Mann,M. and DuBois,R.N. (1999) The role of cyclooxygenases in inflammation, cancer and development. Oncogene, 18, 7908–7916.

20. Prescott,S.M. (2000) Is cyclooxygenase-2 the alpha and omega in cancer? J. Clin. Invest., 105, 1511–1513.

21. Prescott,S.M. and Fitzpatrick,F.A. (2000) Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta, 1470, 69–78.

22. Dixon,D.A. (2004) Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr. Pharm. Des., 10, 635–646.

23. Hwang,D., Scollard,D., Byrne,J. and Levine,E. (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl Cancer Inst., 90, 455–460.

24. Eberhart,C.E., Coffey,R.J., Radhika,R., Giardiello,F.M., Ferrenback,S. and Dubois,R.N. (1994) Uregulation of cyclooxygenase-2 gene expression in human colo-rectal adenosomas and adenosarcinomas. Gastroenterology, 107, 1183–1187.

25. Hida,T., Leyton,J., Makheja,A.N., Ben,A.P., Hla,T., Martinez,A., Mulsine,J., Malkani,S., Chung,P. and Moody,T.W. (1998) Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res., 18, 775–782.

26. Butcher,M., Jones,D.A., Matsunani,N., Groden,J., McIntyre,T.M., Zimmerman,G.A., White,R.L. and Prescott,S.M. (1996) Prostaglandin synthase 2 is aberrantly expressed in human colon cancer: evidence for a transcriptional effect. Proc. Natl Acad. Sci. USA, 93, 4816–4820.

27. Dimberg,J., Samuelsson,A., Hugander,A.M. and Soderkvist,P. (1998) Gene expression of cyclooxygenase-2, group II and cytosolic cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 58, 375–378.

28. Williams,C.S., Tsuji,M., Reese,J., Dey,S.K. and DuBois,R.N. (2000) Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest., 105, 1589–1594.

29. Liu,W., Reinmuth,N., Stoeltzing,O., Parikh,A.A., Tellez,C., Williams,S., Jung,Y.D., Takeda,A., Akagi,M., Bar-Eli,M. et al. (2003) Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res., 63, 3632–3636.

30. Xiong,B., Sun,J.T., Yuan,H.Y., Hu,M.B., Hu,W.D. and Cheng,F.L. (2003) Cyclooxygenase-2 expression and angiogenesis in colorectal cancer. World J. Gastroenterol., 9, 1237–1240.

31. Denkert,C., Winzer,K.J., Muller,B.M., Weichert,W., Pest,S., Kobel,M., Kristiaghen,G., Reles,A., Siegert,A., Gusi,H. and Hauptmann,S. (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer, 97, 2978–2987.

32. Landen,C.N., Mathur,S.P., Richardson,M.S. and Creasman,W.T. (2003) Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am. J. Obstet. Gynecol., 188, 1174–1176.

33. Lewis,J., Gunderson,S. and Mertaj.I.W. (1995) The influence of 5' and 3' end structures on pre-mRNA metabolism. J. Cell Sci., 19 (Suppl.), 13–19.

34. Jacobson,A. and Pelz,S.W. (1996) Intermelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu. Rev. Biochem., 65, 693–739.

35. Sachs,A.B., Sarnow,P. and Hentze,M.W. (1997) Starting at the beginning, middle and end: translation initiation in eukaryotes. Cell, 89, 831–838.

36. Wickens,M., Anderson,P. and Jackson,R.I. (1997) Life and death in the cytoplasm: messages from the 3' end. Curr. Opin. Genet. Dev., 7, 220–232.

37. Colgan,D.F. and Manley,J.L. (1997) Mechanism and regulation of mRNA polyadenylation. Genes Dev., 11, 2755–2766.

38. Edmonds,M. (2002) A history of poly(A) sequences: from formation to factors to function. Prog. Nucleic Acid Res. Mol. Biol., 71, 285–389.

39. Proudfoot,N. (2004) New perspectives on connecting messenger RNA 3' end formation to transcription. Curr. Opin. Cell Biol., 16, 272–278.

40. Wahl,E. and Kuhn,U. (1997) The mechanism of 3' cleavage and polyadenylation of eukaryotic pre-mRNA. Prog. Nucleic Acid Res. Mol. Biol., 57, 41–71.

41. Ryan,K., Calvo,O. and Manley,J.L. (2004) Evidence that polyadenylation factor CPSF-73 is the mRNA 3' processing endonuclease. RNA, 10, 565–573.

42. Tian,B., Hu,J., Zhang,H. and Lutz,C.S. (2005) A large scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res., 33, 201–212.

43. Chen,F., MacDonald,C.C. and Wilusz,J. (1995) Cleavage site determinants in the mammalian polyadenylation signal. Nucleic Acids Res., 23, 2614–2620.

44. Chen,F. and Wilusz,J. (1998) Auxiliary downstream elements are required for efficient polyadenylation of mammalian pre-mRNAs. Nucleic Acids Res., 26, 2891–2898.

45. Gil,A. and Proudfoot,N.J. (1984) A sequence downstream of AAUAAA is required for rabbit beta-globin mRNA 3' end formation. Nature, 312, 473–474.

46. Gil,A. and Proudfoot,N.J. (1987) Position-dependent sequence elements downstream of AAUAAA are required for efficient rabbit beta-globin mRNA formation. Cell, 49, 399–406.

47. McDevitt,M.A., Imperiale,M.J., Ali,H. and Nevins,J.R. (1984) Requirement of a downstream sequence for generation of a poly(A) addition site. Cell, 37, 993–999.

48. Sadofsky,M., Connelly,S., Manley,J.L. and Alwine,J.C. (1985) Identification of a sequence element on the 3' side of AAUAAA which is necessary for simian virus 40 late mRNA 3' end processing. Mol. Cell. Biol., 5, 2713–2719.

49. Conway,L. and Wilkins,M. (1985) A sequence downstream of AAUAAA is required for formation of simian virus 40 late mRNA in 3' termini in frog oocytes. Proc. Natl Acad. Sci. USA, 82, 3949–3953.

50. Wilusz,J. and Shenk,T. (1990) A uridylyl tract mediates efficient heterogeneous nuclear ribonucleoprotein C protein-RNA crosslinking and functionally substitutes for the downstream element of the polyadenylation signal. Mol. Cell. Biol., 10, 6397–6407.

51. Ryner,L.C., Takagaki,Y. and Manley,J.L. (1989) Sequences downstream of AAUAAA signals affect pre-mRNA cleavage and polyadenylation in vitro both directly and indirectly. Mol. Cell. Biol., 9, 1759–1771.

52. Brown,P.H., Tiley,L.S. and Cullen,B.R. (1991) Efficient polyadenylation within the human immunodeficiency type 1 long terminal repeat inhibits polyadenylation of its own pre-mRNA. J. Virol., 65, 3340–3343.

53. Carswell,S. and Alwine,J.C. (1989) Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol. Cell. Biol., 9, 4248–4258.

54. DeZazzo,J.D., Kilpatrick,J.E. and Imperiale,M.J. (1991) Involvement of a downstream sequence element and the G20210A polymorphism: the influence of a competitive environment for mRNA 3' end formation. Nucleic Acids Res., 19, 3559–3569.
58. Gilmartin,G.M., Fleming,E.S. and Oetjen,J. (1992) Activation of HIV-1 pre-mRNA 3' processing in vitro requires both an upstream element and TAR. *EMBO J.*, 11, 4419–4428.

59. Gilmartin,G.M., Fleming,E.S., Oetjen,J. and Gravely,B.R. (1995) CPSF recognition of and HIV-1 mRNA 3' processing enhancer: multiple sequence contacts involved in poly(A) site definition. *Genes Dev.*, 9, 72–83.

60. Sanfalcon,H., Brodmann,P. and Hohn,T. (1991) A dissection of the cauliflower mosaic virus polyadenylation signal. *Genes Dev.*, 5, 141–149.

61. Russnak,R. (1991) Regulation of polyadenylation in hepatitis B virus: stimulation by the upstream activating signal 5's is orientation-dependent, distance-dependent, and additive. *Nucleic Acids Res.*, 19, 6449–6456.

62. Moreira,A., Wollerton,M., Monks,J. and Proudfoot,N.J. (1995) Upstream sequence elements enhance poly(A) site efficiency of the C2 complement gene and are phylogenetically conserved. *EMBO J.*, 14, 3809–3819.

63. Moreira,A., Takagaki,Y., Brackenridge,S., Wollerton,M., Manley,J.L. and Proudfoot,N.J. (1998) The upstream sequence element of the C2 complement poly(A) signal activates mRNA 3' end formation by two distinct mechanisms. *Genes Dev.*, 12, 2522–2534.

64. Natalizio,B.J., Muniz,L.C., Arhin,G.K., Wilusz,J. and Lutz,C.S. (2002) Upstream elements present in the 3' UTR of collagen gene influence the processing efficiency of overlapping polyadenylation signals. *J. Biol. Chem.*, 277, 42733–42740.

65. Schek,N., Cooke,C. and Alwine,J.C. (1992) Definition of the upstream efficiency element of the simian virus 40 late polyadenylation signal. *Cell*, 70, 416–424.

66. Lutz,C.S. and Alwine,J.C. (1994) Direct interaction of the U1snRNP-A protein with the upstream efficiency element of the SV40 late polyadenylation signal. *Genes Dev.*, 8, 576–586.

67. Maniatis,T. and Reed,R. (2002) An extensive network of coupling among gene expression machines. *Nature*, 416, 499–506.

68. Proudfoot,N.J., Furger,A. and Dye,M.J. (2002) Integrating mRNA processing with transcription. *Cell*, 108, 501–512.

69. Zhao,J., Hyman,L. and Moore,C. (1999) Formation of mRNA 3' ends in eukaryotes: mechanism, regulation and interrelationships with other steps in mRNA synthesis. *Microbiol. Mol. Biol. Rev.*, 63, 405–445.

70. Conne,B., Stutz,A. and Vassalli,J.D. (2000) The 3' untranslated region of messenger RNA: a molecular hotspot for pathology? *Nature Med.*, 6, 637–641.

71. Appleby,S.B., Ristimaki,A., Neilson,K., Narko,K. and Hla,T. (1994) Structure of the human cyclo-oxygenase-2 gene. *Biochem. J.*, 302, 723–727.

72. Shaw,G. and Kamen,R. (1986) A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. *Cell*, 46, 659–667.

73. Chen,C.Y. and Shyu,A.B. (1995) AU-rich elements: characterization and importance in mRNA degradation. *Trends Biochem. Sci.*, 20, 465–470.

74. Dean,J.L., Sully,G., Wait,R., Rawlinson,L., Clark,A.R. and Saklatvala,J. (2002) Identification of a novel AU-rich element-binding protein which is related to AUF-1. *Biochem. J.*, 366, 709–719.

75. Dixon,D.A., Tolley,N.D., King,P.H., Nabors,L.B., McIntyre,T.M., Zimmerman,G.A. and Prescott,S.M. (2001) Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. *J. Clin. Invest.*, 108, 1657–1665.

76. Nabors,L.B., Gillespie,G.Y., Harkins,L. and King,P.H. (2001) HuR, a mRNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. *Cancer Res.*, 61, 2154–2161.

77. Sengupta,S., Jan,B.C., Wu,M.T., Paik,J.H., Furneaux,H. and Hla,T. (2003) The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. *J. Biol. Chem.*, 278, 25227–25233.

78. Sawaoka,H., Dixon,D.A., Oates,J.A. and Boutard,O. (2003) Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. *J. Biol. Chem.*, 278, 13928–13935.

79. Dixon,D.A., Balch,G.C., Kedersha,N., Anderson,P., Zimmerman,G.A., Beauchamp,R.D. and Prescott,S.M. (2003) Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. *J. Exp. Med.*, 198, 475–481.

80. Feng,L., Sun,W., Xia,Y., Tang,W.W., Chanmugam,P., Soyoola,E., Wilson,C.B. and Hwang,D. (1993) Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. *Arch. Biochem. Biophys.*, 307, 361–368.

81. Lukiew.J.W. and Bazan,N.G. (1997) Cyclooxygenase 2 RNA message abundance, stability and hypervariability in sporadic Alzheimer neocortex. *J. Neurosci. Res.*, 50, 937–945.

82. Sheets,M.D., Ogg,S.C. and Wikens,M.P. (1990) Point mutations in AAUAAA and the poly(A) addition site: effects on the accuracy and efficiency of cleavage and polyadenylation in vitro. *Nucleic Acids Res.*, 18, 5799–5805.

83. Wilusz,J., Pettine,S.M. and Shenk,T. (1998) Functional analysis of point mutations in the AAUAAA motif of the SV40 late polyadenylation signal. *Nucleic Acids Res.*, 17, 3899–3908.

84. Denome,R.M. and Cole,C.N. (1988) Patterns of polyadenylation site selection in gene constructs containing multiple polyadenylation signals. *Mol. Cell. Biol.*, 8, 4829–4839.

85. Edwalsd-Gilbert,G., Prescott,J. and Falck-Pederson,A.R. (2001) Identification of a novel AU-rich element-binding protein which is related to AUF-1. *Biochem. Biophys. Res. Commun.*, 242, 508–512.